Laman UtamaPTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Tutup sebelumnya
$0.095
Julat tahun
$0.087 - $0.11
Permodalan pasaran
68.91T IDR
Bilangan Purata
62.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
IDX
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(IDR) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 7.91T | 7.16% |
Perbelanjaan pengendalian | 2.29T | 15.55% |
Pendapatan bersih | 573.28B | 6.97% |
Margin untung bersih | 7.25 | -0.14% |
Pendapatan bagi setiap syer | 12.41 | 7.73% |
EBITDA | 874.81B | 1.14% |
Kadar cukai berkesan | 23.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(IDR) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 4.32T | 45.45% |
Jumlah aset | 28.75T | 5.78% |
Jumlah liabiliti | 4.84T | 0.67% |
Jumlah ekuiti | 23.91T | — |
Syer tertunggak | 46.15B | — |
Harga kepada buku | 0.00 | — |
Pulangan pada aset | 6.15% | — |
Pulangan pada modal | 7.16% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(IDR) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 573.28B | 6.97% |
Tunai daripada operasi | 1.16T | 22.56% |
Tunai daripada pelaburan | -176.64B | 33.78% |
Tunai daripada pembiayaan | -421.11B | 51.91% |
Perubahan bersih dalam tunai | 481.86B | 1,978.42% |
Aliran tunai bebas | 752.00B | 13.84% |
Perihal
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Diasaskan
10 Sep 1966
Tapak web
Pekerja
12,924